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Resistant hypertension (RHTN) is deﬁned as blood pressure (BP) that remains uncontrolled in spite of intake of ≥3
antihypertensive medications, ideally prescribed at optimal doses and one of which is a diuretic. The incidence of primary
aldosteronism (PA) in patients with RHTN is estimated in prospective studies to be 14 to 23%, which is higher than in the
general hypertensive population. Patients with PA are at an increased cardiovascular risk, as shown by higher rates of stroke,
myocardial infarction, and arrhythmias compared to hypertensive individuals without PA. Likewise, RHTN is associated with
adverse cardiovascular outcomes, and the contribution of PA to this increased risk is undetermined. Similar to PA, obstructive
sleep apnea (OSA) is closely associated with RHTN, and a causal link between PA, OSA, and RHTN remains to be elucidated. The
addition of MR antagonists to the antihypertensive regimen in patients with RHTN produces a profound BP-lowering eﬀect, and
this eﬀect is seen in patients with or without biochemical evidence of PA, highlighting the role of relative aldosterone excess in
driving treatment resistance in this group of patients.
1.Introduction
Primary aldosteronism (PA) is characterized by the overpro-
duction of the mineralocorticoid hormone aldosterone by
the adrenal gland, a condition that is relatively autonomous
of the renin-angiotensin system (RAS), and nonsuppressible
by sodium loading [1]. The elevated circulating aldosterone
levels lead to potassium loss, hypernatremia, metabolic alka-
losis, and hypertension. The syndrome can be the result of
bilateral hyperplasia of the adrenal glands, unilateral adrenal
hyperplasia, aldosterone producing adrenal adenoma, or
in rare cases, by glucocorticoid-remediable aldosteronism
(GRA).
Early epidemiologic studies have determined the preva-
lence of PA to be <1% of hypertensive patients, particularly
if hypokalemia was used as a sine qua non for its diagnosis
[2–4].Recentstudieshavechallengedthisassumption,which
have reported the prevalence of PA to be about 5–10% in the
general hypertensive population [5–8]. In a study done in
Chile, using the aldosterone to renin ratio (ARR) to screen
for PA and conﬁrming its presence using ﬂudrocortisone
testing,theprevalenceofPAwas6.1%inapopulationofuns-
elected essential hypertensive patients [8]. This prevalence
was noted to rise with increasing severity of hypertension,
such that in patients with Stage III hypertension (classiﬁed
according to Joint National Commission (JNC) 6 criteria,
i.e., BP > 180/100mmHg), the prevalence of PA was 13.2%,
as opposed to 1.99% in patients with Stage I hypertension
(systolic BP [SBP] 140–159mmHg, diastolic BP [DBP] 90–
99mmHg). Further, patients with PA had a higher BP
(164/102±12/10mmHg)thanpatientswithoutPA(156/96±
16/9mmHg,P<. 05)andweretakingmoreantihypertensive
medications at baseline (1.6 ± 0.8v e r s u s1 .2 ± 0.9, P<
.05). In another study done at the Czech Republic involving
over 400 patients with moderate to severe hypertension
(BP > 166/101mmHg), the prevalence of PA was 19% [9].
In this study, screening for PA was undertaken using the
ARR and conﬁrmed by non- or mild suppression of plasma
aldosterone levels after saline infusion, and the elevated BP
levels in the clinic were conﬁrmed by 24-hour ABPM.
PA is particularly common in patients with resistant
hypertension(RHTN),deﬁnedasBPthatremainsabovegoal2 International Journal of Hypertension
in spite of use of at least 3 antihypertensive medications,
ideally prescribed at optimal doses and one of which is a
diuretic [10]. In a large retrospective study involving 1,616
patients with RHTN who were referred to a specialty clinic
in Greece, the prevalence of PA (screened for using the
aldosterone-to-renin ratio [ARR] and conﬁrmed by intra-
venous saline loading or ﬂudrocortisone suppression and
further conﬁrmed by assessing response to spironolactone
monotherapy) was determined to be 11.3% [11]. Prospective
studies have found an even higher prevalence of PA in
patients with RHTN. Among 88 patients with RHTN who
were consecutively referred to the hypertension clinic of the
University of Alabama at Birmingham (UAB), 18 patients
(20%) were conﬁrmed to have PA, based on a high 24-
hour urinary aldosterone excretion (>12µg/24hr) paired
with a suppressed plasma renin activity level (<1ng/ml/hr)
during a high sodium diet (urinary sodium excretion
>200mEq/24hr) [12]. This high prevalence of PA in patients
with moderate to severe hypertension has been conﬁrmed
in other prospective studies done elsewhere. Investigators
from Oslo, Norway found a PA prevalence of 21% of patients
withRHTN[13].Inauniversity-basedhypertensionclinicin
Seattle, Washington, the PA prevalence was 17% in patients
with severe and/or poorly controlled hypertension (BP >
140/90mmHg) [14]. Lastly, in a study done on 100 diabetic
patients with RHTN, PA was conﬁrmed in 14% of the
study patients, using oral or intravenous saline loading [15].
Overall, these studies show that PA prevalence is higher
(14–21%) in patients with moderate to severe hypertension
on multiple antihypertensive medications, compared to the
general hypertensive population.
2.Prognosis
High aldosterone levels lead to increased sodium and water
reabsorption (and consequently potassium loss) in the distal
nephron, acting via mineralocorticoid receptors (MRs) that
regulate gene transcription. Aldosterone also exerts rapid,
nongenomic cellular eﬀects on MRs found in nonepithelial
tissue, thereby inﬂuencing cell volume, oxidation-reduction
state, and vascular function [16]. These eﬀects are linked
to the development of vascular stiﬀness and ﬁbrosis, par-
ticularly in large arteries, the heart, and the kidney [17].
Taken together, these eﬀects act in concert to raise BP
and contribute to target organ damage in hypertensive
individuals with aldosterone excess and may partly explain
treatment resistance in those with more severe hypertension.
Aldosterone excess has been linked to the development
and progression of several cardiovascular diseases, notably
hypertension, congestive heart failure, coronary artery dis-
ease, chronic kidney disease, and stroke. In the Framingham
Oﬀspring Study, higher baseline serum aldosterone levels
were associated with an increased risk of BP elevation
or development of hypertension after four years in 1688
normotensive individuals (mean age 55 years, 58% women)
[18]. Using multivariate analysis, there was a 16% increased
riskofanelevationinBP(P = .002)anda17%increasedrisk
ofdevelopmentofhypertensionperquartileincrementinthe
serum aldosterone level, and the highest quartile of serum
aldosterone, compared to the lowest quartile, was associated
with a 1.61-fold risk of development of hypertension (95%
CI 1.05 to 2.46).
Beyond its eﬀects on BP, the presence of PA is associ-
ated with increased carotid intima thickness, higher pulse
wave velocity (a marker of increased arterial stiﬀness),
and impaired ﬂow-mediated brachial artery dilation (which
is an indicator of endothelial dysfunction) compared to
hypertensive patients without PA [19, 20]. Left ventricular
wall thickness is higher, and there is greater incidence of
diastolic dysfunction as measured by tissue Doppler imaging
in patients with PA compared to matched hypertensive
controls [21]. In the kidney, apart from its eﬀects on renal
sodium handling, excess aldosterone induces early kidney
damage. Patients with PA have a higher urinary albumin
excretion rate compared to matched hypertensive controls,
with a preserved glomerular ﬁltration rate (which is an early
manifestation of kidney disease) [22].
Comparing hypertensive patients with PA to those
without biochemical evidence of aldosterone excess, the
former had a greater incidence of stroke (both hemorrhagic
and ischemic, odds ratio [OR] 4.2, 95% conﬁdence interval
[CI] 2.0 to 8.6, P<. 001), myocardial infarction (OR 6.5,
95% CI 1.5 to 27.4, P<. 005), and atrial ﬁbrillation (OR
12.1, 95% CI 3.2 to 45.2, P<. 0001) [23]. Similarly, in
another study, the presence of PA was associated with a
higherincidenceofmyocardialinfarction,strokeortransient
ischemic attack, and sustained arrhythmias compared to
patientswithessentialhypertensionwithoutPA[24].Inboth
studies,thediﬀerenceswerenotedinspiteofsimilarBPlevels
between the two groups, further supporting the concept
that aldosterone excess produces additional adverse cardio-
vascular eﬀects independent of BP. Moreover, the subtype
of PA (aldosterone producing adenoma or bilateral adrenal
hyperplasia) did not appear to inﬂuence the cardiovascular
risk.
In the same regard, patients with RHTN have greater
cardiovascular risk compared to those who do not have
RHTN. Patients with RHTN have a higher incidence of
concomitant diabetes, kidney disease, and obstructive sleep
apnea, all of which are independent risk factors for the
development of cardiovascular disease [25, 26]. RHTN is
associated with the increased incidence of left ventricular
hypertrophy, retinopathy, nephropathy, and carotid intimal
disease,whichareconsideredsigns oftargetorgandamagein
hypertensive disease [27, 28]. Lastly, small outcome studies
have shown that patients with RHTN have increased rates
of stroke, myocardial infarction, and congestive heart failure
compared to patients without RHTN [29, 30]. The extent to
which PA contributes to this increased risk in patients with
RHTN is unknown.
3.PrimaryAldosteronism, ObstructiveSleep
Apnea, andResistant Hypertension
Obstructive sleep apnea (OSA) is strongly associated with
the risk of having hypertension and the risk of developingInternational Journal of Hypertension 3
hypertension [31]. Moreover, it appears that greater severity
ofhypertensionisassociatedwithincreasedriskofOSA,such
that OSA is particularly common in patients with RHTN.
In a prospective study on 41 patients with RHTN, 83%
were diagnosed with OSA (deﬁned as apnea-hypopnea index
[AHI] > 10 events/hour) after overnight polysomnography
(PSG), and OSA was more prevalent (96 versus 65%, P =
.014) and more severe (mean AHI 32 versus 14, P = 0004)
in men than in women [25]. These results were conﬁrmed
in our study involving 71 patients with RHTN, where the
prevalence of OSA was determined to be 85% and is also
more common and more severe in men than in women
[32].
Increasing severity of OSA also is associated with dif-
ﬁculty to control hypertension. In 257 patients with OSA
who are adherent to a stable antihypertensive regimen
for 6 months, those who were ineﬀectively treated (BP >
140/90mmHg) had a higher AHI (44 events/hr) compared
to those with controlled BP (33 events/hr, P<. 005) in spite
of having similar nocturnal oxygenation and after adjusting
for age, gender, and body mass index [33]. As a corollary,
in an observational study on patients with RHTN and OSA,
treatment of OSA with continuous positive airway pressure
(CPAP) allowed deescalation of antihypertensive drug ther-
apy (by dose reduction or discontinuation of one or more
drugs) in 71% of study patients [34]. This eﬀect was not
seen in patients without RHTN. The results of a prospective
study in patients with RHTN and OSA largely conﬁrm
these ﬁndings. Treatment with CPAP (mean use of 5.8
hours/night) on top of the usual antihypertensive drug regi-
men signiﬁcantly reduced mean 24-hour BP by 10/7mmHg
at the 3rd month followup, and the BP lowering eﬀect was
greatest for those who used CPAP longest each night (i.e.,
better compliance) [35]. While OSA is a known risk factor
for the development of hypertension and likely contributes
to treatment resistance, the above results also suggest that
the reverse may be true; that RHTN may predispose to or
aggravate OSA. Their common link, however, remains to be
elucidated.
In 325 newly diagnosed hypertensive patients who
were screened for the presence of OSA and evaluated by
overnight polysomnography, 53 patients were conﬁrmed to
have OSA [36]. Out of these 53 patients, 18 patients had
PA, based on results of saline infusion testing. Considering
that both PA and OSA are common in patients with
RHTN, it is interesting to note that in 71 patients with
RHTN who underwent biochemical testing for PA and
overnight PSG, the plasma aldosterone concentration was
positively correlated with AHI (Pearson’s r = 0.44, P =
.0002) [32]. This association was not seen in 29 con-
trol patients without RHTN, where the median plasma
aldosterone level was lower than in patients with RHTN
and not correlated to the AHI. These results suggest that
in patients with RHTN, PA may contribute to increased
severity of OSA but does not exclude the reverse: that OSA
stimulates aldosterone release in these patients. Currently,
we are undertaking a prospective evaluation to test this
hypothesis.
4. Treatment
Surgical treatment (unilateral adrenalectomy) should be
oﬀered to patients with unilateral adrenal disease who are
eligible for surgery. In a number of reports, unilateral
adrenalectomy has been shown to improve BP control
and incidence of hypokalemia. In patients who are unable
or unwilling to undergo surgery, treatment with an MR
antagonist should be initiated.
Treatment of aldosterone excess with either spironolac-
tone or unilateral adrenalectomy was found to reverse the
increaseincardiovascularriskfoundinhypertensivepatients
with PA [23]. After a 12-year followup, patients with PA
who were treated accordingly had similar rates of cardio-
vascular events as hypertensive patients without PA. Better
cardiovascular outcomes were seen in younger patients and
in those with a shorter duration of disease, highlighting the
importance of early recognition and treatment to reverse the
adverse eﬀects of excess aldosterone.
4.1. Mineralocorticoid Receptor Antagonists. Spironolactone,
a direct antagonist of the MR, is a formidable add-on agent
to the antihypertensive regimen in patients with RHTN, who
are taking at least 3 antihypertensive medications to control
BP.Whenaddedtoaregimenthattypicallyalreadyincludesa
diuretic,anRASblockerandaCCBorBB,spironolactone(at
a dose of 12.5 to 25mg/day) lowers BP by as much as 21/10±
21/14mmHg at 6 weeks and 25/12 ± 20/12mmHg after 6
months (Figure 1)[ 37]. This eﬀect was similar in patients
with or without evidence of aldosterone excess, as well as
in African American and Caucasian patients. In another
study,incorporatingtheresultsof24-hourambulatoryblood
pressure monitoring, higher doses of spironolactone (25 to
100mg/day) reduced 24-hour mean BP by 16/9mmHg, and
control (daytime BP < 135/85) was achieved in 48% of
patients[38].Inbothstudies,similardegreesofBPreduction
were achieved regardless of baseline plasma aldosterone or
PRAvalues.Thisunderscoresthecontributoryroleofrelative
aldosterone excess to treatment resistance in this group of
patients, such that even those with presumably low levels of
aldosterone beneﬁt from MR blockade.
This importance of relative aldosterone excess in pro-
moting treatment resistance is further emphasized in a com-
parison between spironolactone added to an ACE inhibitor
or an ARB versus the combination of an ACE inhibitor
and an ARB in treating patients with RHTN [39]. In this
open-label prospective crossover study, 44 patients with
RHTN received a second RAS blocker (ACE inhibitor or
ARB) for 12 weeks, then subsequently given spironolactone
(25mg/day or higher) after a 4-week washout period.
Greater BP reduction was achieved when spironolactone was
added to an ACE inhibitor or an ARB (24-hour mean BP
reduction of 21/9mmHg, which is compatible with other
trials of spironolactone as an add-on agent) versus dual
RAS blockade (24-hour mean BP reduction of 7/3mmHg),
allowing 53.8% of patients receiving spironolactone to attain
target BP, as opposed to only 25.6% of those on dual RAS
blocker therapy. The results suggest that aldosterone excess
playsabiggerroleinthepathogenesisoftreatmentresistance,4 International Journal of Hypertension
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Figure 1: BP reduction achieved after low-dose spironolactone was added to the antihypertensive regimen in patients with RHTN, with
(ﬁlled bars) or without (open bars) PA [37].
and that the hypersecretion of aldosterone is relatively
autonomous of the RAS, so the magnitude of BP lowering
is greater in patients given the MR antagonist compared
to those on dual blockade. Further, since the study largely
excluded patients with PA, the results show that resistant
hypertensive patients in general have an element of relative
aldosterone excess, even while measured aldosterone levels
fall within the “normal” range.
Some of the more common adverse eﬀects seen with
spironolactone treatment are breast tenderness, gynecomas-
tia, erectile dysfunction, and menstrual irregularities, which
result from the binding of spironolactone to androgen recep-
tors,preventingitsinteractionwithdihydrotestosterone.The
incidence of these adverse eﬀects is rare, reported by about
2–9% of study patients, and is reversible after discontinuing
treatment. Eplerenone, another MR antagonist, binds more
selectively to the MR and has a lower aﬃnity for androgen
receptors and thus does not have the antiandrogen eﬀects. It
is eﬀective in treating patients with RHTN. After receiving
eplerenone (at a dose of 50 to 100mg/day, titrated to achieve
BP < 140/90mmHg) on top of a three-drug regimen for
12 weeks, oﬃce BP was reduced by 18/8mmHg, and 24-
hour mean BP decreased by 12/6mmHg (P<. 001) [40].
Again, these eﬀects were independent of baseline plasma
aldosterone and PRA levels.
A head-to-head comparison between spironolactone
and eplerenone in patients with primary (not resistant)
hypertension and bilateral adrenal hyperplasia showed that
the two agents achieved similar degrees of BP lowering
in patients with PA [41]. Spironolactone was administered
at 400mg/day (which is a higher dose than usual), while
eplerenone was given at 150mg/day. In spite of the large dose
used in the study, only 2 (out of 17) patients who received
spironolactone developed painful gynecomastia after 16
weeks of followup, and this was resolved after the patients
were shifted to eplerenone. A direct comparison of these two
agents in patients with RHTN has not been conducted.
Hyperkalemia can also result from treatment with MR
antagonists, particularly in the setting of multidrug therapy
that includes RAS blockers, which can also raise serum
potassium levels, or in patients with chronic kidney disease.
This eﬀect is likewise reversed by discontinuing the MR
antagonist or reducing the dose. The incidence of hyper-
kalemia, however, is low. Out of 76 patients who were
given spironolactone for 6 months, only 2 (2.6%) developed
hyperkalemia (K>5.5mEq/L) [36]. In patients given
eplerenone,theserumpotassiumincreasedbyameanof0.30
± 0.45mEq/L after initiation of eplerenone treatment, and
mild hyperkalemia (serum potassium 5.5 to 6mEq/L) was
seen in only two patients (out of 52, or 3.8%), despite being
on an ACE inhibitor or an ARB concomitantly [39].
Beyond BP lowering, treatment with MR antagonists
also reverses or attenuates cardiovascular injury mediated
by excess aldosterone, particularly the nongenomic eﬀects,International Journal of Hypertension 5
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Figure 2: Changes in the apnea-hypopnea index (AHI), hypoxic
index (HI), and AHI during supine position or rapid-eye move-
ment (REM) sleep in patients with resistant hypertension before
(baseline) and after 8 weeks of add-on spironolactone. ∗P<. 05
compared to baseline [44].
which lead to tissue ﬁbrosis, arterial stiﬀness, and increased
oxidative stress. In patients with RHTN (with or without
PA), spironolactone (at an initial dose of 25mg/day then
forcetitrated to 50mg/day after 4 weeks) reduced left ven-
tricular mass index at the 3rd and 6th month followup [42].
The degree of LV regression achieved with spironolactone
treatment was greater for patients with PA compared to
those without PA (22 versus 12%, resp., P<. 001 relative
to baseline values). Further, spironolactone given to patients
withbothRHTNandPAfor6monthssigniﬁcantlydecreased
brain natriuretic peptide values from baseline, an eﬀect
that was not seen in those with normal or low aldosterone
levels, indicating a prominent diuretic eﬀect even when
administered on top of chronic thiazide diuretic treatment.
In another study involving patients with RHTN and PA,
treatment with low-dose spironolactone (12.5 to 25mg/day)
for 3 months signiﬁcantly increased ﬂow-mediated dilation
of the brachial artery, indicating improvement of endothelial
function,andthiseﬀectwasindependentofthechangeinBP
[43].
Lastly, spironolactone reduced the severity of OSA in
patients with RHTN [44].Inaprospectiveevaluationinvolv-
ing 12 patients with RHTN in whom spironolactone (25–
50mg/day) was added to a stable antihypertensive regimen,
there were signiﬁcant reductions in the AHI (39.8 ± 19.5
versus 22 ± 6.8 events/hour, P<. 05), hypoxic index (13.6 ±
10.8v e r s u s6 .7±6.6 events/hour, P<. 05), and clinic and 24-
hour ambulatory BP on the 8th week followup, and plasma
renin activity was increased (Figure 2). Although the study
was small and did not have an active control group, this
study lends support to the concept that aldosterone excess
contributes to the severity of OSA in patients with RHTN.
5. Summary
RHTN and PA are each associated with increased cardio-
vascular risk in hypertensive patients. Aldosterone excess is
believed to contribute signiﬁcantly to uncontrolled BP in
patients with RHTN, as shown by a higher prevalence of PA
in patients with RHTN and a signiﬁcant BP-lowering eﬀect
produced by MR antagonists, particularly spironolactone,
when added to a multidrug antihypertensive regimen that
typically already includes a diuretic and an RAS blocker.
This eﬀect was seen in both patients with and without
PA, showing that even in those patients without elevated
aldosterone levels (by current laboratory standards), there is
some element of relative aldosterone excess that contributes
to the raised BP. Further, treatment with MR antago-
nists produces cardiovascular beneﬁts beyond BP lowering
(including reduction of the severity of OSA), showing that
aldosterone also plays a direct role in the development
of target organ damage, arterial stiﬀness, and endothelial
dysfunction, mostly mediated via nongenomic mechanisms.
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